Physician profile

Jeremy Perse

Foot & Ankle Surgery · Cleveland, OH

NPI 1811243397

$5,242.30

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Foot & Ankle Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$256.37

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Integra Lifesciences Corporation $4,608.94 2019-2024 Integra, Primatrix, Integra Dermal Regeneration Template
Medtronic Vascular, INC. $200.98 2019
Stryker Corporation $147.68 2019-2021
Bioness INC $137.27 2021
Kci USA, INC. $72.29 2021
Smith+Nephew, INC. $33.84 2019
Melinta Therapeutics, LLC $24.69 2019
Organogenesis INC. $16.61 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jeremy Perse

$5,242.30

in general payments reported 2019-2025

Years
2019-2024
Top company
Integra Lifesciences Corporation

https://glasscript.com/doctor/386309/jeremy-perse

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.